Schmidt L E, Tofteng F, Strauss G I, Larsen F S
Department of Hepatology, Rigshospitalet, University Hospital, Copenhagen, Denmark.
Scand J Gastroenterol. 2004 Oct;39(10):974-80. doi: 10.1080/00365520410003227.
Liver failure is associated with low concentrations of branched-chain amino acids and high concentrations of most other amino acids. In this study the effect of treatment with the Molecular Adsorbents Recirculating System (MARS) on arterial amino acid levels and cerebral amino acid metabolism was examined in patients with severe hepatic encephalopathy.
The study included seven patients with hepatic encephalopathy from fulminant hepatic failure (FHF) and five patients with hepatic encephalopathy from acute-on-chronic liver failure (AoCLF). Cerebral blood flow and cerebral arteriovenous differences in amino acids were measured before and after 6 h of treatment with MARS.
During MARS treatment, the total arterial amino acid concentration decreased by 20% from 8.92 +/- 7.79 mmol/L to 7.16 +/- 5.64 mmol/L (P < 0.05). The concentration decreased in all amino acids with the exception of the branched-chain amino acids. Fischer's ratio of branched-chain to aromatic amino acids increased from 0.73 +/- 0.47 to 0.91 +/- 0.54 (P < 0.05). A net cerebral efflux of amino acids in patients with FHF (8.94 +/- 8.34 micromol/100 g/min) as well as AoCLF (7.35 +/- 24.97 micromol/100 g/min) was not affected by the MARS treatment. MARS had no effect on the cerebral metabolic rate of any single amino acid in either group.
MARS treatment tends to normalize the arterial amino acid concentrations in patients with hepatic encephalopathy. Even though the overall reduction in plasma amino acids and improvement in amino acid dysbalance may well be beneficial, it was not accompanied by any immediate improvement in cerebral amino acid metabolism in patients with FHF or AoCLF.
肝衰竭与支链氨基酸浓度降低及大多数其他氨基酸浓度升高有关。本研究在严重肝性脑病患者中检测了分子吸附再循环系统(MARS)治疗对动脉氨基酸水平及脑氨基酸代谢的影响。
本研究纳入了7例暴发性肝衰竭(FHF)所致肝性脑病患者和5例慢性肝功能衰竭急性发作(AoCLF)所致肝性脑病患者。在MARS治疗6小时前后测量脑血流量及脑动静脉氨基酸差异。
在MARS治疗期间,总动脉氨基酸浓度从8.92±7.79 mmol/L降至7.16±5.64 mmol/L,下降了20%(P<0.05)。除支链氨基酸外,所有氨基酸浓度均下降。支链氨基酸与芳香族氨基酸的费希尔比值从0.73±0.47增至0.91±0.54(P<0.05)。FHF患者(8.94±8.34 μmol/100 g/min)和AoCLF患者(7.35±24.97 μmol/100 g/min)的脑氨基酸净流出量不受MARS治疗影响。MARS对两组中任何单一氨基酸的脑代谢率均无影响。
MARS治疗倾向于使肝性脑病患者的动脉氨基酸浓度正常化。尽管血浆氨基酸的总体降低及氨基酸失衡的改善可能有益,但FHF或AoCLF患者的脑氨基酸代谢并未立即得到改善。